Concentrated ultra-rapid-acting insulin (Albireo Pharma)

N/A

Report date: 2022/11/25 17:22:56

Base Information

Drug NameConcentrated ultra-rapid-acting insulin (Albireo Pharma)
Drug Alias Name浓缩的超速效胰岛素制剂BIOD-531
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlbireo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiodel Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A